ArticleThe Journal of experimental medicine2022
Autoantibodies against type I IFNs in patients with critical influenza pneumonia.
2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
16.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification, in Patients Admitted to Intensive Care for Severe Influenza Respiratory Infection, of a Predictive Biomarker of Respiratory Distress
Early Interferon-beta Treatment for West-Nile Virus Infection
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases.Journal of clinical immunology · 2026Pooled it
- High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C.Journal of human immunity · 2026Article
- Prevalence of neutralizing autoantibodies against type I interferon in dengue patients.Journal of human immunity · 2026Article
- Autoantibodies neutralizing type I interferons in older twin pairs: Low concordance.Journal of human immunity · 2026Article
- Highly neutralizing anti-IFN-ω autoantibodies underlie severe pediatric adenovirus infection.Journal of human immunity · 2026Article
- Autoantibodies neutralizing type I interferons in COVID-19 patients from southern Brazil.Journal of human immunity · 2026Article
- CONSTANCES, the French nationwide population cohort: major accomplishments.European journal of epidemiology · 2026Article
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Autoantibodies against type I interferons in patients with zoonotic H7N9 influenza: an observational case-control study.EBioMedicine · 2026Observational
- Allogeneic hematopoietic cell transplantation for partial RAG deficiency in children and adults: Excellent outcomes with a reduced-intensity posttransplantation cyclophosphamide-based approach.The Journal of allergy and clinical immunology · 2026Article
- Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.Cell · 2026Article
- Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.Journal of human immunity · 2026Article
- Toward a monogenic architecture of human infections: From 1996 to 2026.Journal of human immunity · 2026Review
- RNA-binding proteins Zfp36l1 and Zfp36l2 protect against premature thymic involution.Cellular & molecular immunology · 2026Article
- Article
- Transfer of IgG from long COVID patients induces symptomology in mice.Cell reports. Medicine · 2026Article
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.medRxiv : the preprint server for health sciences · 2026Article
- Viral infection and brain inflammation with seizures in PARK7 deficiency.Journal of human immunity · 2026Article
- Expanding the scope of human immunology in theJournal of human immunity · 2026Article
- Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis.The Journal of experimental medicine · 2026Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
76 authors at 20 institutions in 11 countries.
Qian Zhang *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.ORCID 0000-0002-9040-3289
Andrés Pizzorno *CIRI, Centre International de Recherche en Infectiologie - Team VirPath, Univ Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS Lyon, Lyon, France.ORCID 0000-0002-0918-6804
Lisa Miorin *Dept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-0989-3178
Paul Bastard *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.ORCID 0000-0002-5926-8437
Adrian Gervais *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-1083-5787
Tom Le Voyer *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-7253-3135
Lucy Bizien *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-9163-9122
Jeremy ManryLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-5998-2051
Jérémie RosainLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-2822-161X
Quentin PhilippotLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0003-3429-9605
Kelian GoavecLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-0277-6692
Blandine PadeyCIRI, Centre International de Recherche en Infectiologie - Team VirPath, Univ Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS Lyon, Lyon, France.ORCID 0000-0002-2159-6507
Anastasija CupicDept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-1291-1042
Emilie LaurentCIRI, Centre International de Recherche en Infectiologie - Team VirPath, Univ Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS Lyon, Lyon, France.ORCID 0000-0002-8993-8905
Kahina SakerJoint Research Unit, Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France.ORCID 0000-0001-8825-5400
Martti VankerInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0002-6232-7717
Karita SärekannuInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0002-5984-668X
COVID Human Genetic Effort
Etablissement Français du Sang Study Group
Constances Cohort
3C-Dijon Study
Cerba HealthCare Group
Lyon Antigrippe Working Group
REIPI INF Working Group
Tamara García-SalumDept. of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0002-0170-9965
Marcela FerresDept. of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0001-9415-4657
Nicole Le CorreDept. of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0002-9361-4049
Javier Sánchez-CéspedesCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-2707-1979
María Balsera-ManzaneroCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-5667-925X
Jordi CarratalaCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-3209-2563
Pilar Retamar-GentilCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0003-2147-809X
Gabriela Abelenda-AlonsoBellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.ORCID 0000-0001-8158-9934
Adoración ValienteCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0002-1468-2458
Pierre TiberghienEtablissement Francais Du Sang, La Plaine-Saint Denis, Saint-Denis, France.ORCID 0000-0002-9310-8322
Marie ZinsUniversity of Paris Cite, University of Paris-Saclay, UVSQ, INSERM UMS11, Villejuif, France.ORCID 0000-0002-4540-4282
Stéphanie DebetteUniversity of Bordeaux, INSERM, Bordeaux Population Health Center, UMR1219, Bordeaux, France.ORCID 0000-0001-8675-7968
Isabelle MeytsLaboratory for Inborn Errors of Immunity, Dept. of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.ORCID 0000-0003-1214-0302
Filomeen HaerynckDept. of Pediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent, PID Research Laboratory, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0001-9161-7361
Riccardo CastagnoliLaboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-0029-9383
Luigi D NotarangeloLaboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-8335-0262
Luis I Gonzalez-GranadoImmunodeficiencies Unit, Hospital October 12, Research Institute Hospital October 12, School of Medicine, Complutense University, Madrid, Spain.ORCID 0000-0001-6917-8980
Nerea Dominguez-PinillaPediatrics Service, Hematology and Oncology Unit, University Hospital 12 October, Madrid, Spain.ORCID 0000-0002-8452-7963
Evangelos AndreakosLaboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.ORCID 0000-0001-5536-1661
Vasiliki TriantafylliaLaboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.ORCID 0000-0001-5832-4014
Carlos Rodríguez-GallegoDept. of Immunology, University Hospital of Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-4344-8644
Jordi Solé-ViolánDept. of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-0483-4470
José Juan Ruiz-HernandezDept. of Internal Medicine, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, Las Palmas de Gran Canaria, Spain.ORCID 0000-0001-5393-5529
Felipe Rodríguez de CastroDept. of Respiratory Diseases, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-6812-2739
José FerreresCritical Care Unit, Hospital Clínico de Valencia, Valencia, Spain.ORCID 0000-0002-8227-0877
Marisa BrionesDept. of Respiratory Diseases, Hospital Clínico y Universitario de Valencia, Valencia, Spain.ORCID 0000-0002-2815-4234
Joost WautersDept. of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-5983-3897
Lore VanderbekeDept. of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-3364-1213
Simon FeysDept. of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-7516-9471
Chen-Yen KuoLaboratory of Human Immunology and Infectious Disease, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-6277-6408
Wei-Te LeiLaboratory of Human Immunology and Infectious Disease, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0003-1677-8901
Cheng-Lung KuLaboratory of Human Immunology and Infectious Disease, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-0643-2256
Galit TalMetabolic Clinic, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.ORCID 0000-0002-1166-3956
Amos EtzioniMetabolic Clinic, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.ORCID 0000-0002-0381-8049
Suhair HannaMetabolic Clinic, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.ORCID 0000-0001-8438-845X
Thomas FournetEtablissement Français Du Sang, Université de Franche-Comté, Besançon, France.ORCID 0000-0002-4309-3775
Jean-Sebastien CasalegnoVirology Laboratory, CNR des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0003-3271-9856
Gregory QueromesCIRI, Centre International de Recherche en Infectiologie - Team VirPath, Univ Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS Lyon, Lyon, France.ORCID 0000-0001-8176-3955
Laurent ArgaudMedical Intensive Care Dept., Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.ORCID 0000-0002-4565-2454
Etienne JavouheyPediatric Intensive Care Unit, Hospices Civils de Lyon, Hopital Femme Mère Enfant, Lyon, France.ORCID 0000-0002-6480-0758
Manuel Rosa-CalatravaCIRI, Centre International de Recherche en Infectiologie - Team VirPath, Univ Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS Lyon, Lyon, France.ORCID 0000-0002-7559-9527
Elisa CorderoCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-7766-7266
Teresa AydilloDept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0003-3086-1058
Rafael A MedinaDept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-5013-6884
Kai Kisand *Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0002-5426-4648
Anne Puel *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.ORCID 0000-0003-2603-0323
Emmanuelle Jouanguy *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.ORCID 0000-0002-7358-9157
Laurent Abel *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.ORCID 0000-0001-7016-6493
Aurélie Cobat *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.ORCID 0000-0001-7209-6257
Sophie Trouillet-Assant *CIRI, Centre International de Recherche en Infectiologie - Team VirPath, Univ Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, ENS Lyon, Lyon, France.ORCID 0000-0001-6439-4705
Adolfo García-Sastre *Dept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-6551-1827
Jean-Laurent Casanova *St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY.ORCID 0000-0002-7782-4169
Inserm · FRUniversité Claude Bernard Lyon 1 · FRInstituto de Salud Carlos III · ESPontificia Universidad Católica de Chile · CLRambam Health Care Campus · ILNational Institutes of Health · USAcademy of Athens · GRChang Gung University · TWÉtablissement Français du Sang · FRHoward Hughes Medical Institute · USKU Leuven · BEGhent University Hospital · BEUniversidad Fernando Pessoa Canarias · ESUniversité de Bordeaux · FRUniversity of Tartu · EEIcahn School of Medicine at Mount Sinai · USResearch Institute Hospital 12 de Octubre · ESEmory University · USTechnion – Israel Institute of Technology · ILUniversidad de Las Palmas de Gran Canaria · ES
Funding
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MTRANSFORMING TRANSLATIONAL SCIENCE AND EDUCATION TO BENEFIT HUMAN HEALTHUL1RR024143 · NCRR · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2006 to 2011
$49.1MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MSARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2MTechnology Development Project - Increasing the complexity of ex vivo human airway models for studying immune response to viral infectionU19AI142733 · NIAID · JACKSON LABORATORY · PI Adolfo Garcia-Sastre, Anna Karolina Palucka · 2019 to 2026
$23.1MViral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)U19AI168631 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Harm van Bakel · 2022 to 2026
$14.4MMonogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7MInborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7MHoward Hughes Medical InstituteMedical Research Council MR/S032304/1NCATS NIH HHS UL1 TR001866NCRR NIH HHS UL1 RR024143NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI088364NIAID NIH HHS R01 AI163029NIAID NIH HHS U19 AI135972NIAID NIH HHS U19 AI142733NIAID NIH HHS U19 AI168631
Abstract
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10-5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10-10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
Indexed as
AutoantibodiesInfluenza, HumanInterferon Type IPneumoniaCOVID-19HumansYellow Fever VaccineAutoantibodiesInterferon Type IYellow Fever Vaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02392858ClinicalTrials.gov
NCT06510426ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.